Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) gapped up prior to trading on Wednesday . The stock had previously closed at $126.21, but opened at $126.31. Jazz Pharmaceuticals PLC shares last traded at $128.05, with a volume of 371,049 shares changing hands.

A number of analysts recently issued reports on JAZZ shares. Piper Jaffray Cos. reissued a “buy” rating and issued a $186.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, May 31st. Leerink Swann reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, May 31st. SunTrust Banks Inc. reaffirmed a “buy” rating and set a $210.00 price objective (up from $200.00) on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, June 2nd. Deutsche Bank AG reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, June 2nd. Finally, Goldman Sachs Group Inc. initiated coverage on Jazz Pharmaceuticals PLC in a research report on Monday, June 6th. They set a “buy” rating and a $196.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and fourteen have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $185.67.

The firm’s 50-day moving average is $131.65 and its 200-day moving average is $139.67. The stock has a market capitalization of $7.80 billion, a PE ratio of 22.65 and a beta of 0.93.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/jazz-pharmaceuticals-plc-jazz-shares-gap-up-to-126-31.html

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $2.63 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.80 by $0.17. The company had revenue of $381 million for the quarter, compared to the consensus estimate of $376.40 million. Jazz Pharmaceuticals PLC had a net margin of 25.46% and a return on equity of 28.39%. The firm’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same period last year, the company posted $2.41 earnings per share. On average, analysts predict that Jazz Pharmaceuticals PLC will post $10.08 earnings per share for the current fiscal year.

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $150.00, for a total transaction of $150,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Karen L. Smith bought 580 shares of the stock in a transaction dated Wednesday, July 13th. The shares were bought at an average cost of $143.63 per share, with a total value of $83,305.40. Following the completion of the acquisition, the chief marketing officer now directly owns 13,574 shares of the company’s stock, valued at approximately $1,949,633.62. The disclosure for this purchase can be found here. Insiders own 3.90% of the company’s stock.

Several institutional investors have recently bought and sold shares of JAZZ. Norges Bank acquired a new position in shares of Jazz Pharmaceuticals PLC during the fourth quarter valued at about $48,545,000. Fiera Capital Corp acquired a new position in shares of Jazz Pharmaceuticals PLC during the second quarter valued at about $46,955,000. Prudential Financial Inc. increased its position in shares of Jazz Pharmaceuticals PLC by 49.2% in the first quarter. Prudential Financial Inc. now owns 608,077 shares of the specialty pharmaceutical company’s stock valued at $79,385,000 after buying an additional 200,560 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Jazz Pharmaceuticals PLC by 1,044.1% in the first quarter. Renaissance Technologies LLC now owns 215,100 shares of the specialty pharmaceutical company’s stock valued at $28,081,000 after buying an additional 196,300 shares in the last quarter. Finally, Polar Capital LLP acquired a new position in shares of Jazz Pharmaceuticals PLC during the second quarter valued at about $25,560,000. 88.25% of the stock is owned by institutional investors.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.